JP2019509345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509345A5 JP2019509345A5 JP2019500212A JP2019500212A JP2019509345A5 JP 2019509345 A5 JP2019509345 A5 JP 2019509345A5 JP 2019500212 A JP2019500212 A JP 2019500212A JP 2019500212 A JP2019500212 A JP 2019500212A JP 2019509345 A5 JP2019509345 A5 JP 2019509345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- total weight
- sodium phenylbutyrate
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076939A JP2022106927A (ja) | 2016-03-15 | 2022-05-09 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
| JP2024055290A JP2024081748A (ja) | 2016-03-15 | 2024-03-29 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308614P | 2016-03-15 | 2016-03-15 | |
| US62/308,614 | 2016-03-15 | ||
| PCT/US2016/057415 WO2017160345A1 (en) | 2016-03-15 | 2016-10-17 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076939A Division JP2022106927A (ja) | 2016-03-15 | 2022-05-09 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509345A JP2019509345A (ja) | 2019-04-04 |
| JP2019509345A5 true JP2019509345A5 (enExample) | 2019-11-28 |
| JP7136763B2 JP7136763B2 (ja) | 2022-09-13 |
Family
ID=59847918
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500212A Active JP7136763B2 (ja) | 2016-03-15 | 2016-10-17 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
| JP2022076939A Withdrawn JP2022106927A (ja) | 2016-03-15 | 2022-05-09 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
| JP2024055290A Pending JP2024081748A (ja) | 2016-03-15 | 2024-03-29 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076939A Withdrawn JP2022106927A (ja) | 2016-03-15 | 2022-05-09 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
| JP2024055290A Pending JP2024081748A (ja) | 2016-03-15 | 2024-03-29 | フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20170266115A1 (enExample) |
| EP (2) | EP4104822A1 (enExample) |
| JP (3) | JP7136763B2 (enExample) |
| KR (3) | KR20250150154A (enExample) |
| AU (1) | AU2016398029B2 (enExample) |
| BR (1) | BR112018068665B1 (enExample) |
| CA (1) | CA3017573A1 (enExample) |
| CY (1) | CY1125450T1 (enExample) |
| DK (1) | DK3429559T3 (enExample) |
| ES (1) | ES2922749T3 (enExample) |
| HR (1) | HRP20220856T1 (enExample) |
| HU (1) | HUE059630T2 (enExample) |
| IL (3) | IL322955A (enExample) |
| LT (1) | LT3429559T (enExample) |
| MX (2) | MX391305B (enExample) |
| PL (1) | PL3429559T3 (enExample) |
| PT (1) | PT3429559T (enExample) |
| RS (1) | RS63383B1 (enExample) |
| SA (1) | SA518400020B1 (enExample) |
| SG (1) | SG11201807979SA (enExample) |
| SI (1) | SI3429559T1 (enExample) |
| SM (1) | SMT202200386T1 (enExample) |
| WO (1) | WO2017160345A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391305B (es) | 2016-03-15 | 2025-03-21 | Acer Therapeutics Inc | Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. |
| US11583542B2 (en) * | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| US20230248657A1 (en) * | 2020-07-07 | 2023-08-10 | Acer Therapeutics Inc. | Methods of administering taste masked phenylbutyrate and compositions therefor |
| JP2023553274A (ja) * | 2020-11-18 | 2023-12-21 | エフビー－エイチアールエス リミテッド ライアビリティ カンパニー | ドフェチリド及びメキシレチンを含有する組成物並びにその使用 |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| IT202100019613A1 (it) | 2021-07-23 | 2023-01-23 | Kolfarma S R L | Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale |
| CN216570857U (zh) * | 2021-08-11 | 2022-05-24 | Acer治疗公司 | 改善药物物质适口性的剂型和多个剂型 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| AR034813A1 (es) | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| US20040152784A1 (en) * | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| FR2850275B1 (fr) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
| JP2005060310A (ja) | 2003-08-13 | 2005-03-10 | Towa Yakuhin Kk | 不快な味をマスキングする経口投与用製剤 |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| MXPA06011765A (es) * | 2004-04-12 | 2006-12-15 | Pfizer Prod Inc | Farmacos de sabor enmascarado en multiparticulados que se rompen. |
| NZ580972A (en) * | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| JP4706785B2 (ja) * | 2008-09-30 | 2011-06-22 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| BR112012001465B1 (pt) * | 2009-07-24 | 2021-08-31 | Baylor College Of Medicine | Uso de um fenilbutirato, sal, éster ou pró-fármaco do mesmo |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| EP2389932A1 (en) * | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
| US20130323362A1 (en) | 2010-12-06 | 2013-12-05 | Degama Berrier Ltd. | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
| US20140178484A1 (en) * | 2011-05-16 | 2014-06-26 | Sun Pharma Advanced Research Company Ltd. | Multi-particulate pharmaceutical composition |
| WO2012168882A1 (en) | 2011-06-07 | 2012-12-13 | SPAI Group Ltd. | Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof |
| RU2014100048A (ru) | 2011-06-22 | 2015-07-27 | Гмп-Орфан | Соль 4-фенилбитурата, предназначенная для лечения болезни моторных нейронов или метаболического заболевания при ректальном введении |
| EP3318247A1 (en) * | 2011-08-12 | 2018-05-09 | Boehringer Ingelheim Vetmedica GmbH | Taste masked pharmaceutical composition |
| EP2599477A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| US8993041B2 (en) | 2012-10-15 | 2015-03-31 | New Jersey Institute Of Technology | Taste masked active pharmaceutical powder compositions and processes for making them |
| CN105560203A (zh) | 2013-01-28 | 2016-05-11 | 万平 | 定位速释生物粘附剂及其制备方法和应用 |
| JP6147711B2 (ja) | 2014-05-26 | 2017-06-14 | 富士フイルム株式会社 | 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法 |
| MX391305B (es) | 2016-03-15 | 2025-03-21 | Acer Therapeutics Inc | Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. |
-
2016
- 2016-10-17 MX MX2018011229A patent/MX391305B/es unknown
- 2016-10-17 KR KR1020257031993A patent/KR20250150154A/ko active Pending
- 2016-10-17 EP EP22167705.7A patent/EP4104822A1/en active Pending
- 2016-10-17 JP JP2019500212A patent/JP7136763B2/ja active Active
- 2016-10-17 PT PT168947869T patent/PT3429559T/pt unknown
- 2016-10-17 KR KR1020247025507A patent/KR102865751B1/ko active Active
- 2016-10-17 SG SG11201807979SA patent/SG11201807979SA/en unknown
- 2016-10-17 HU HUE16894786A patent/HUE059630T2/hu unknown
- 2016-10-17 PL PL16894786.9T patent/PL3429559T3/pl unknown
- 2016-10-17 BR BR112018068665-4A patent/BR112018068665B1/pt active IP Right Grant
- 2016-10-17 LT LTEPPCT/US2016/057415T patent/LT3429559T/lt unknown
- 2016-10-17 EP EP16894786.9A patent/EP3429559B1/en active Active
- 2016-10-17 KR KR1020187029452A patent/KR102690703B1/ko active Active
- 2016-10-17 CA CA3017573A patent/CA3017573A1/en active Pending
- 2016-10-17 DK DK16894786.9T patent/DK3429559T3/da active
- 2016-10-17 AU AU2016398029A patent/AU2016398029B2/en active Active
- 2016-10-17 IL IL322955A patent/IL322955A/en unknown
- 2016-10-17 RS RS20220651A patent/RS63383B1/sr unknown
- 2016-10-17 SI SI201631567T patent/SI3429559T1/sl unknown
- 2016-10-17 IL IL296490A patent/IL296490B1/en unknown
- 2016-10-17 US US15/295,881 patent/US20170266115A1/en not_active Abandoned
- 2016-10-17 SM SM20220386T patent/SMT202200386T1/it unknown
- 2016-10-17 HR HRP20220856TT patent/HRP20220856T1/hr unknown
- 2016-10-17 WO PCT/US2016/057415 patent/WO2017160345A1/en not_active Ceased
- 2016-10-17 ES ES16894786T patent/ES2922749T3/es active Active
-
2018
- 2018-09-13 IL IL261777A patent/IL261777B2/en unknown
- 2018-09-13 SA SA518400020A patent/SA518400020B1/ar unknown
- 2018-09-14 MX MX2022003969A patent/MX2022003969A/es unknown
-
2020
- 2020-01-17 US US16/746,186 patent/US11433041B2/en active Active
-
2021
- 2021-03-09 US US17/196,599 patent/US11202767B2/en active Active
- 2021-03-09 US US17/196,416 patent/US11154521B2/en active Active
-
2022
- 2022-05-09 JP JP2022076939A patent/JP2022106927A/ja not_active Withdrawn
- 2022-07-12 CY CY20221100475T patent/CY1125450T1/el unknown
- 2022-09-02 US US17/902,358 patent/US20230133629A1/en not_active Abandoned
-
2024
- 2024-03-29 JP JP2024055290A patent/JP2024081748A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509345A5 (enExample) | ||
| EP3154523B1 (en) | Formulation for oral administration containing mesalazine | |
| CN102970983B (zh) | 耐受酒精的口服药物制剂 | |
| JP6316376B2 (ja) | アマンタジン組成物および使用方法 | |
| US11903908B2 (en) | Methods of administering amantadine | |
| JP5491859B2 (ja) | リポ酸のペレット | |
| JP2008280351A5 (enExample) | ||
| CN104606146B (zh) | 一种埃索美拉唑镁肠溶微丸制剂及其制备方法 | |
| WO2005048996A2 (en) | Modified release dosage forms of skeletal muscle relaxants | |
| JP2009537611A5 (ja) | リポ酸のペレット | |
| KR20090053858A (ko) | 이온성 수-불용성 중합체에 미세매몰된 화합물을 포함하는 약학적 고체 투여 형태 | |
| JP2012519725A (ja) | 治療薬の徐放性組成物 | |
| JP2008519070A5 (enExample) | ||
| HRP20220856T1 (hr) | Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe | |
| AU2015254874A1 (en) | Extended release liquid compositions of metformin | |
| EP3269363B1 (en) | Stabilized formulations of cns compounds | |
| KR20170086063A (ko) | 디메틸 푸마르산염을 포함하는 제약학적 비드 제제 | |
| JP2008501741A (ja) | 多層制御放出性メチルフェニデートペレット | |
| JP2008501741A6 (ja) | 多層制御放出性メチルフェニデートペレット | |
| JP2008519069A5 (enExample) | ||
| RU2007115537A (ru) | Новые препараты ингибиторов протонного насоса в виде пеллет с модифицированным высвобождением | |
| BRPI0720958A2 (pt) | Omposição de duloxetina | |
| JP2009510027A (ja) | ベンラファキシン塩酸塩の制御放出性の医薬組成物、及びその調製方法 | |
| WO2013158638A1 (en) | Stable dosage forms of skeletal muscle relaxants with extended release coating | |
| WO2010037849A1 (en) | Duloxetine enteric pellets |